

Remarks

Applicants provide detailed remarks and arguments concerning the amendments submitted in view of the previous Examiner's communication of 3/9/04. In the previous communication, the examiner rejected the claims on the following basis: 1) Rejection of Claim 28 as being duplicative; 2) Rejection of Claims 1-6, 11-12, 26, 30-32, and 35 under 35 USC § 103; 3) Rejection of Claim 26 under 35 USC § 103

Claim 28

Examiner has indicated that the Applicant has cancelled claim 28, but has also submitted amendments therefore. After the Examiner's review of amended claim 28, it appears to differ from claim 26 only in the functional language of the preamble. The examiner has deduced that it was, in fact, Applicant's intent to cancel claim 28, and thus, it has not been examined, and remains cancelled.

Applicants have formally cancelled Claim 28, thereby rendering the present rejection moot.

Rejection of Claims 1-6, 11-12, 26, 30-32, and 35 under 35 USC § 103

Claims 1-6, 11, 12, 26, and 30-31 were rejected by the Examiner under 35 U.S.C. 103(a) as being unpatentable over Helmus et al. (US 5,447,724) in view of Fearnot et al. (US 5,609,629).¹

¹ Helmus was cited for teaching substantially all the claimed subject matter including an implantable medical device (figure 1, col. 3, line 31), having a tissue-contacting surface formed of polyurethane or silicone (col. 2, lines 41-42) which has a drug such as heparin (col. 6, line 51) or a steroid (col. 6, line 55) intimately mixed into it (col. 4, lines 20-24 and col. 9, lines 45-46). The Examiner specifically points out that col. 71 lines 57 -62 specify the OUTER layer, not the reservoir layer. In col. 7, lines 57 -62, Helmus teaches that the agent in the outer layer is put there to produce a "gradual release effect" alluding to the slower release of the agent at first from the outer layer and gradual increase in the release rate as the more concentrated stores of the same agent start to seep through the outer layer from the inner reservoir. Since this teaches that the agent in the outer layer can be the same as in the inner layer, and that the

Fearnot (US 5,609,629) teaches the application teaches that the medical device should have at least **two** coatings. First there should be a “bioactive layer.” Then applied over the “bioactive layer” there should be at least one porous topcoat layer

“Applicants have discovered that the degradation of an agent, a drug or a bioactive material applied to such a device can be avoided by covering the agent, drug or bioactive material with a porous layer of a biocompatible polymer . . .”[Fearnot et al., US 5,609,629 - Column 3, lines 6-12]

Fearnot teaches that drug release polymers coated to medical devices should have a top porous layer is preferably made of polyamide, parylene, or a parylene derivative (Col. 3, lines 50-57) which are applied by vapor deposition (Col. 3, lines 50-54) or plasma deposition (Col. 4, lines 13-24). Fearnot limits this selection when he says “A vast range of drugs, medicants and materials can be employed as the bioactive material in the layer 18 (“bioactive layer”), so long as the selected material can survive exposure to the vacuum drawn during vapor deposition or plasma deposition” (Col. 7, lines 32-36).

Helmus also requires having **two** coats. Helmus requires a bottom drug reservoir layer and a topcoat layer to control delivery of the drug. Minimally the “reservoir” layer requires the physical formation of drug reservoir pockets – these pockets are formed from porogens initially placed in the coating (referred by Helmus as

reservoir agent can be a steroid (col. 6, line 55), is interpreted by the Examiner as referring to physiologically active agents in both the reservoir and outer layer. The Examiner indicates that Helmus teaches all the claimed subject matter except for the steroid being a glucocorticosteroid such dexamethasone. Fearnot is relied on by the Examiner for teaching the use of dexamethasone in a drug embedded outer layer of a catheter. The Examiner, thereby concludes, it would have been obvious to one of ordinary skill in the art to use dexamethasone as taught by Fearnot as one of the steroids broadly mentioned by Helmus (col. 6, line 54-55) since dexamethasone is a well-known anti-inflammatory steroid, and as demonstrated by Helmus it is known to use it as the bioactive component of a bioactive surface on a catheter.

In the Examiner “Response to Arguments, the Examiner points out that Applicants specification on page 13, line 26 indicates that the agent and polymer, are “intimately mixed by [1] blending or [2] using a solvent in which they are both soluble . . .”, and that Applicants appear to be arguing that the term “intimately mixed” means only the second possibility [2], that is, use of a solvent.

“elutable components” – see Column 6, lines 25-29 and Col. 7, lines 15-20). As such, Helmus does not appear to teach the tissue-contacting polymer surface of the catheter is dissolvably mixed with the drug because there are defined particulates in the polymer layer. The outer polymeric surface-layer overlying a inner polymer layer that incorporates the agent (23) (see figures 1b and 1c, or 2b and 2c) and has an elutable component (22) which is eroded to form pores to the inner polymer area containing agent (23). The “elutable component” is required to be particulate in nature in order to form the structural pores in the polymer layer. No where is there formed a therapeutic polymer reservoir without particulates.

Applicant’s invention as now claimed is distinguishable over Helmus in view of Fearnot in several respects. First, both Helmus and Fearnot contain a drug reservoir layer. Applicants contain the drug in the applied overcoating – but not in the lead body or through forming drug reservoir pockets. Both Helmus and Fearnot use an overcoating to control the release of the drug from the undercoat. Applicants lead body is positionally analogous to the drug reservoir layer of Fearnot and Helmus, in that it lies next to the conductor; however, Applicants do not incorporate drug into this layer, whereas they cited references have this as a pre-requisite. Applicants do not have a drug reservoir undercoat. Additionally, neither Helmus or nor Fearnot teach a controlled release mechanism from the overcoat by having the polymer and drug co-solvated in the same solvent with the requirement that there are no particulates. This clearly distinguishes over Helmus where the top-layer contains elutable micron-sized particulates that form channels from removal of the elutable components.

In conclusion, neither Fearnot nor Helmus teach an overcoating of a polymer with an active agent that does not contain particulates and the main insulative body lead surrounding the conductor is free of active agent. Applicants do not have drug reservoirs because the active agent is solublized in the polymer overcoat. In view of these differences over Helmus in view of Fearnot, Applicants respectfully request the present rejections be removed.

Rejection of Claim 26 under 35 USC § 103


With regard to the method claims, claim 26, which claims a method of use, the examiner points out that the claim only contains one broad method step of "implanting," the rest is merely structure. The Examiner further points out that claims 30-32, and 35 merely claim the basic assembly steps necessary to put anything together (e.g. "coupling").

First, Applicants have cancelled claim 26, 31, 32, and 35. Applicants have amended their claim 30 to provide steps to the process of overcoating the insulative body lead with a single layer containing the active agent, wherein the applied overcoating does not contain micro-particulates and the elongated insulative lead body is not formed with an active agent. In view of having a novel and non-obvious overcoating process step, the applicants respectfully request the present reject be removed.

Conclusion

In view of the submitted cancelled claims, amended claims, and arguments submitted with the present response, Applicants' believe the claimed subject matter is novel and unobvious over the prior art and anxiously await the examiner's review and approval to issue the remaining claims. Should the Examiner have any question regarding the submitted amendments and arguments or wish to discuss the application, Applicants are available for discussion through their attorney at the number provided below.

Respectfully submitted,

 12/29/04

Kenneth J. Collier
Attorney/Agent for Applicants
Registration No. 34,982
Phone: 763-505-2521

Medtronic, Inc.
Patent Department
710 Medtronic Parkway
Minneapolis, MN 55432